Foundation
The Khavinson Lineage
Six decades of biochemical and clinical work establishing short-peptide bioregulation as a distinct pharmacological category. The institutional research program that characterized the privileged subclass.
Read →Research
Four decades of empirical foundation.
The institutional research program, the cross-species evidence, the peer-reviewed literature, and the patent portfolio that anchors the discipline.
In This Section
Four bodies of evidence.
Mammalian Evidence
Cross-Species Evidence
In-vivo demonstration of bioregulator activity across mouse, rat, rabbit, dog, primate, and bovine models. The cross-species consistency that supports translation to clinical use.
Read →Peer Review
Published Literature
The body of peer-reviewed research from institutional laboratories across Russia, Ukraine, Italy, South Korea, and the United Kingdom. Bibliographic anchors for the discipline.
Read →Intellectual Property
Patent Portfolio Overview
The provisional patent portfolio filed March 2026 covering proprietary Ac-X-NH2 dual-terminus modified compositions, methods of use, and formulations across multiple indication areas.
Read →